echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Stroke: Association between beta-blocker or statin use and risk of cavernous malformation bleeding

    Stroke: Association between beta-blocker or statin use and risk of cavernous malformation bleeding

    • Last Update: 2022-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cerebral cavernous malformations (CCMs) can manifest as seizures, intracranial hemorrhage, focal neurological deficits, or incidentally on brain magnetic resonance imaging


    Seizures, intracranial hemorrhage, and focal neurological deficits can also be detected incidentally on MRI of the brain


    A study published in Stroke, an authoritative journal in the field of cardiovascular disease, aims to determine the relationship between beta-blocker or statin use and future symptomatic intracranial hemorrhage or intracranial cavernous malformation (CCM).


    The population-based Scottish cohort of adults with intracranial vascular malformations prospectively identified adult residents of Scotland with a first diagnosis of CCM between 1999-2003 or 2006-2010


    63 (21%) of 300 adults used beta-blockers (27/63 [43%] propranolol) and 73 (24%) used 3634 visits/years of follow-up statins


    CONCLUSIONS: The use of beta-blockers, rather than statins, reduces the risk of intracranial hemorrhage or persistent/progressive focal neurological deficits in patients with CCM


    The use of beta-blockers (rather than statins) reduces the risk of intracranial hemorrhage or persistent/progressive focal neurological deficits in patients with CCM


    Original source:

    Original source:

    Susanna M.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.